RxDoctor Payments Data

Terrie Branson

Acute Care · Flower Mound, TXNPI 1104367168

Payments from drug & device makers

$4,934in general payments, 2019–2025

Across 279 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$1K
  • Novartis$655
  • Merck$627
  • Pfizer$409
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$370
  • Boehringer Ingelheim$294
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$4,930100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,934 in reported general payments places this provider in the 90th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$76,220
Medicare patients
456
Services billed
1,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban201$204,667
CamzyosMavacamten16$134,336
EntrestoSacubitril/Valsartan41$62,036
JardianceEmpagliflozin41$49,761
XareltoRivaroxaban19$30,624
BrilintaTicagrelor26$26,905
Repatha SureclickEvolocumab11$8,344
Metoprolol Succinate227$3,144
Amlodipine Besylate217$1,385
Carvedilol169$1,343
Valsartan49$1,235
Diltiazem 24hr Er (Cd)Diltiazem Hcl48$1,219
Potassium Chloride72$1,162
Rosuvastatin Calcium124$1,149
Olmesartan Medoxomil84$1,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$409$204,667201 claims
E.r. Squibb & Sons, L.L.C.Camzyos$1,326$134,33616 claims
NovartisEntresto$655$62,03641 claims
Boehringer IngelheimJardiance$294$49,76141 claims
Johnson & JohnsonXarelto$130$30,62419 claims
AstraZenecaBrilinta$33$26,90526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,323 acute care providers in Texas.

Other acute care in Flower Mound

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →